Literature DB >> 8879253

The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials.

M Markman.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8879253     DOI： 10.1007/bf01221187

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  7 in total

Review 1.  High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.

Authors:  D M Eddy
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

2.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Authors:  F A Holmes; R S Walters; R L Theriault; A D Forman; L K Newton; M N Raber; A U Buzdar; D K Frye; G N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  1991-12-18       Impact factor: 13.506

3.  Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Authors:  A D Seidman; A Tiersten; C Hudis; M Gollub; S Barrett; T J Yao; J Lepore; T Gilewski; V Currie; J Crown
Journal:  J Clin Oncol       Date:  1995-10       Impact factor: 44.544

4.  Evaluation of patients with advanced cancer using the Karnofsky performance status.

Authors:  J W Yates; B Chalmer; F P McKegney
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

5.  Importance of prognostic factors in cancer clinical trials.

Authors:  R Simon
Journal:  Cancer Treat Rep       Date:  1984-01

6.  Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Authors:  L Gianni; E Munzone; G Capri; F Villani; C Spreafico; E Tarenzi; F Fulfaro; A Caraceni; C Martini; A Laffranchi
Journal:  J Natl Cancer Inst       Date:  1995-08-02       Impact factor: 13.506

Review 7.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245
  7 in total
  2 in total

1.  Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

2.  Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.

Authors:  Garrett Jensen; Chad Tang; Kenneth R Hess; Andrew J Bishop; Hubert Y Pan; Jing Li; James N Yang; Nizar M Tannir; Behrang Amini; Claudio Tatsui; Laurence Rhines; Paul D Brown; Amol J Ghia
Journal:  J Radiosurg SBRT       Date:  2017
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.